Entrada Therapeutics Analyst Ratings
Entrada Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Entrada Therapeutics, Maintains $20 Price Target
TD Cowen Reaffirms Their Buy Rating on Entrada Therapeutics Inc (TRDA)
Oppenheimer Initiates Coverage On Entrada Therapeutics With Outperform Rating, Announces Price Target of $22
Entrada Therapeutics Analyst Ratings
HC Wainwright & Co. Maintains Buy on Entrada Therapeutics, Lowers Price Target to $20
Entrada Therapeutics Analyst Ratings
Positive Prospects for Entrada Therapeutics Despite FDA Hold: An Analyst's Buy Rating Justification
Entrada Therapeutics' Promising Phase 1 Trial and Broad Tissue Distribution Profile Underpin Buy Rating
TD Cowen Remains a Buy on Entrada Therapeutics Inc (TRDA)
HC Wainwright & Co. Reiterates Buy on Entrada Therapeutics, Maintains $25 Price Target
Entrada Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA), Aurinia Pharmaceuticals (AUPH) and Aquestive Therapeutics (AQST)
HC Wainwright & Co. Reiterates Buy on Entrada Therapeutics, Maintains $25 Price Target
Entrada Therapeutics Analyst Ratings
Entrada Therapeutics Inc (TRDA) Gets a Hold From Goldman Sachs
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Entrada Therapeutics Inc (TRDA) and Minerva Neurosciences (NERV)
HC Wainwright & Co. Reiterates Buy on Entrada Therapeutics, Maintains $25 Price Target
Entrada Therapeutics Analyst Ratings